89bio (ETNB) | Stock Overview & Key Data
89bio Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $47.25 on March 2, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
89bio
ETNB
|
2.20B Mid-cap | 0.27% | 0.95% | 55.72% | 85.04% | 170.31% | 62.36% | 69.60% | -39.87% | -28.65% | -28.65% | -28.65% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.03% | -0.35% | -9.68% | -7.51% | -5.26% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -1.40% | -12.73% | -19.27% | -14.47% | -20.27% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Moderna
MRNA
|
20.96B Large-cap | 3.05% | 3.72% | -1.55% | 94.84% | 58.98% | 77.67% | -63.84% | -77.10% | 153.71% | 153.71% | 153.71% |
|
Bio-Techne
TECH
|
9.07B Mid-cap | 5.74% | -7.11% | -10.77% | -20.32% | -14.75% | 6.78% | -37.73% | -51.28% | 86.91% | 161.27% | 281.12% |
|
Blueprint Medicines
BPMC
|
8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 61.42% | 61.42% | 12.60% | 149.54% | 73.38% | 370.76% | 598.65% | 598.65% |
Ownership & Short Interest
Calculate Your 89bio Investment Returns
Long-Term Investment Performance Analysis
89bio stock price in Nov 2019 was $20.80, A $1,000.00 lump sum investment in 89bio made 6 years ago would be worth approximately $713.46 today, representing a negative return of -28.65%. This translates to an annualized return (CAGR) of -5.48%.
5 Years 11 Months Investment Scenario (Nov 2019 - Oct 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ETNB's 52-week high and low?
- In the last 52 weeks, 89bio reached a high of $15.06 (on September 18, 2025) and a low of $4.16 (on April 9, 2025).
- What is the market cap and P/E ratio for ETNB?
- Curious about 89bio's size and valuation? Its market capitalization stands at 2.20B. When it comes to valuation, the P/E ratio (trailing twelve months) is -4.23, and the forward P/E (looking ahead) is -5.17.
- Does ETNB pay dividends? If so, what's the yield?
- As for dividends, 89bio isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are 89bio's main competitors or similar companies to consider before investing?
When looking at 89bio, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Moderna
MRNA20.96B Healthcare Biotechnology 77.67% -63.84% Bio-Techne
TECH9.07B Healthcare Biotechnology 6.78% -37.73% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for 89bio Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of 89bio's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -86.86%, the Debt to Equity ratio from the most recent quarter is 7.21, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ETNB?
- Looking at 89bio's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of ETNB stock is held by insiders and institutions?
- Wondering who owns 89bio stock? Company insiders (like executives and directors) hold about 0.60% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 103.69%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.